CR2 and neoplasm: Interestingly, using a therapeutic approach aimed at tumour-targeted complement inhibition, Elvington et al. demonstrated that C3 inhibition (using recombinant protein CR2-Crry) enhances the therapeutic efficacy of radiotherapy, but in a neutrophil-dependent manner [45].